10-Q: ORIC Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

ORIC Pharmaceuticals' third quarter 2024 report highlights increased R&D spending, a net loss, and sufficient cash to fund operations into late 2026.

Summary

• ORIC Pharmaceuticals reported a net loss of $34.6 million for the three months ended September 30, 2024, and a net loss of $91.5 million for the nine months ended September 30, 2024.
• Research and development expenses increased to $31.2 million for the quarter and $82.1 million for the nine-month period, driven by the advancement of ORIC-114 and ORIC-944.
• The company's cash, cash equivalents, and investments totaled $282.4 million as of September 30, 2024.
• ORIC believes its current resources will fund operations into late 2026.
• The company completed a private placement of 12,500,000 shares of common stock at $10.00 per share, resulting in net proceeds of $124.8 million in January 2024.
• All pre-funded warrants were exercised on July 8, 2024, resulting in the issuance of 2,857,104 shares of common stock.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company has a solid cash position and is advancing its clinical programs, the increasing losses and R&D expenses, along with the inherent risks of drug development, temper the overall sentiment. The collaborations are a positive sign, but the financial challenges are significant.

Positives

• The company has sufficient cash, cash equivalents, and investments to fund operations into late 2026.
• ORIC successfully completed a private placement, raising $124.8 million in net proceeds.
• The company is advancing its clinical-stage product candidates, ORIC-114 and ORIC-944, with ongoing clinical trials.
• ORIC has entered into clinical trial collaborations with Bayer and Johnson & Johnson to evaluate ORIC-944 in combination with their respective AR inhibitors.

Negatives

• The company reported a net loss of $34.6 million for the third quarter of 2024 and $91.5 million for the nine months ended September 30, 2024.
• Research and development expenses have increased significantly, reaching $31.2 million for the quarter and $82.1 million for the nine-month period.
• The company has an accumulated deficit of $526.5 million as of September 30, 2024.

Risks

• The company has a limited operating history and has incurred significant losses since inception.
• ORIC is dependent on the success of its product candidates, ORIC-114, ORIC-944, and ORIC-533.
• Clinical trials may not demonstrate safety and efficacy to the satisfaction of regulatory authorities.
• The company faces significant competition in the biotechnology and pharmaceutical industries.
• Third-party manufacturers may encounter difficulties in production or supply chain.
• The company may not be able to obtain or maintain regulatory approval of its product candidates in various jurisdictions.
• The company may be subject to unfavorable third-party coverage and reimbursement practices.
• The company may be subject to product liability claims.
• The company may be unable to attract and retain highly skilled executive officers and employees.
• The company may be unable to protect its intellectual property and proprietary technologies.
• The company is dependent on third parties for production, preclinical studies and clinical trials of its product candidates.
• The company's stock price is volatile and may be subject to fluctuations.

Future Outlook

ORIC expects its current cash, cash equivalents, and investments will be sufficient to fund its current operating plan into late 2026. The company also anticipates that its research and development expenses will increase substantially in the foreseeable future as it continues to advance its product candidates.

Management Comments

• Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date of the issuance of these financial statements.

Industry Context

The report reflects the ongoing challenges and high costs associated with clinical-stage biopharmaceutical development, particularly in oncology. The collaborations with Bayer and Johnson & Johnson highlight the industry trend of combining novel therapies with established treatments to improve patient outcomes. The company's focus on overcoming resistance in cancer aligns with the broader industry's efforts to address unmet medical needs in oncology.

Comparison to Industry Standards

• ORIC's increased R&D spending is consistent with other clinical-stage biotech companies focused on advancing their pipelines.
• The reported net losses are typical for companies in this phase of development, as they are investing heavily in clinical trials and research.
• The cash runway into late 2026 is a positive sign, indicating a relatively strong financial position compared to some peers.
• The collaborations with Bayer and Johnson & Johnson are similar to strategic partnerships seen in the industry, where companies combine their assets to maximize potential.
• Companies like Mirati Therapeutics (now part of Bristol Myers Squibb) and Voronoi Inc., which ORIC has licensing agreements with, are also focused on developing novel cancer therapies, indicating a competitive landscape.

Stakeholder Impact

• Shareholders may be concerned about the increasing net losses, but reassured by the company's cash position and ongoing clinical development.
• Employees are likely to be impacted by the company's growth and the need for additional personnel.
• Customers (potential patients) may benefit from the development of new cancer therapies.
• Suppliers and creditors may be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• The company expects to report updated Phase 1b data for ORIC-114 in the first half of 2025.
• ORIC intends to evaluate strategic partnerships to develop ORIC-533 in combination with other immune-based antimyeloma therapies.
• The company will continue to advance its product candidates through preclinical studies and clinical trials.

Key Dates

Keywords

ORIC Pharmaceuticals, clinical-stage biopharmaceutical, cancer, ORIC-114, ORIC-944, ORIC-533, research and development, clinical trials, private placement, net loss, financial results, biotechnology, oncology, EGFR, HER2, PRC2, CD73